2015
DOI: 10.1016/j.pvr.2015.06.006
|View full text |Cite
|
Sign up to set email alerts
|

European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination

Abstract: In a project coordinated by the International Agency for Research on Cancer (IARC) 31 experts from 11 European countries and IARC have developed supplements to the current European guidelines for quality assurance in cervical cancer screening. The supplements take into account the potential of primary testing for human papillomavirus (HPV) and vaccination against HPV infection to improve cervical cancer prevention and control and will be published by the European Commission in book format. They include 62 reco… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
248
2
8

Year Published

2016
2016
2024
2024

Publication Types

Select...
9

Relationship

3
6

Authors

Journals

citations
Cited by 225 publications
(261 citation statements)
references
References 30 publications
3
248
2
8
Order By: Relevance
“…The VALGENT objectives are in agreement with priorities defined by the World Health Organisation [13] and new European Guidelines in Quality Assurance in Cervical Cancer Screening, which are currently in press [6,14,15].…”
Section: Overall Objectivesmentioning
confidence: 97%
See 1 more Smart Citation
“…The VALGENT objectives are in agreement with priorities defined by the World Health Organisation [13] and new European Guidelines in Quality Assurance in Cervical Cancer Screening, which are currently in press [6,14,15].…”
Section: Overall Objectivesmentioning
confidence: 97%
“…Several countries have recently switched towards HPV-based screening or are in the process of planning this change [15,40,41]. Enrolment of study subjects will therefore include a consecutive series of women participating in HPV-based cervical cancer screening enriched with HPV positive women.…”
Section: Adaptation Of the Valgent Protocolsmentioning
confidence: 99%
“…Concurrent testing (cotesting) with both the HPV-DNA assay and cytology is presently recommended by most societies in the USA but not in Europe [11,26]. Primary screening with only HPV testing has been challenged by some authors who have highlighted the improved detection by cotesting and suggested it is insufficiently sensitive alone [19,27,28,29].…”
Section: Introductionmentioning
confidence: 99%
“…In Europe, the majority of countries adhere to the recommended screening interval of 3-5 years; however, in some countries (Germany, Austria, and Luxembourg) screening is carried out every year. Current European guidelines from 2015 emphasize that despite the convincing evidence for more efficacious screening using HPV primary testing, appropriate screening policy and program organization are essential to achieving an acceptable balance between benefits and harms of any screening program [20]. These principles are particularly important in HPV primary screening in order to avoid substantial increases in the number of women with positive test results leading to additional colposcopies and treatment in the absence of any additional benefit for participants.…”
Section: Cervical Cancer Screeningmentioning
confidence: 99%